Archive for the ‘bioengineering’ category: Page 12

Aug 17, 2023

Durham gene editing firm strikes big deal; it’s ‘right-sized;’ 80 employees exit

Posted by in categories: bioengineering, biotech/medical, finance

DURHAM – A big licensing deal potentially worth hundreds of millions of dollars with an Austrlia-based company at the same time also has triggered what Precision Biosciences calls a “right-sized” organization of the company.

“Prior to the announcement, we had 190 employees, with 110 going forward with Precision. Most of the 80 employees went with Imugene, with the remainder parting ways with a reduction in force,” Mei Burris, director of investor relations and finance for the company,” told WRAL TechWire.

What “right-sized” means was not immediately explained in the company’s announcement Tuesday night after the markets closed. The company’s stock is trading at under $1 and it lost $12 million in its most recent quarter ending June 30.

Aug 17, 2023

Connective Tissue Cells Reprogrammed Into Muscle Stem Cells Without Genetic Engineering

Posted by in categories: bioengineering, biotech/medical, genetics

A new method allows large quantities of muscle stem cells to be safely obtained in cell culture. This provides a potential for treating patients with muscle diseases – and for those who would like to eat meat, but don’t want to kill animals.

Aug 13, 2023

The World’s First Genetically Engineered Wheat Is Here

Posted by in categories: bioengineering, genetics

In October 2020, Argentina approved the world’s first genetically engineered wheat for cultivation and consumption. Production expanded dramatically in 2021, and will continue to expand in 2022, after Argentina received regulatory approval in late 2021 for exports to Brazil, a major consumer of Argentina’s wheat.

The lessons from Argentina’s experience are important as other countries decide whether they want to follow suit. Argentina’s genetically engineered, drought-tolerant wheat — named HB4 — could have large environmental benefits, but other countries’ choices will determine their scale.

Argentina is increasingly struggling with drought and saw an opportunity for HB4 wheat to help stabilize production and revenue. Yields have been steadily decreasing since 2017, partially due to drought, with the 2020/21 season yields the second-lowest in ten years. Yields in the 2021/22 season bounced back thanks to sufficient rainfall at critical times. HB4 wheat, genetically engineered to be drought resistant, can help protect against such variability by maintaining high yields even under drought conditions. HB4’s drought resistance gene comes from sunflowers, so it qualifies as transgenic — containing genes from a different species — and therefore as bioengineered, genetically modified, or a GMO.

Aug 12, 2023

Could Rotifers be the Next Great Laboratory Model?

Posted by in categories: bioengineering, biotech/medical

Rotifers are multicellular, microscopic marine animals that live in soils and freshwater environments. They are transparent and can be easily grown in large numbers. As such, they have been used in some laboratories as research subjects for many years. Now scientists have found a way to manipulate the rotifer genome, which can make them far more useful for many different research applications.

In new work reported in PLOS Biology, scientists used the CRISPR-Cas9 gene editing tool to alter two rotifer genes. These edits were then passed down to future generations of rotifers. This effort can now help others use these organisms in their laboratories.

Aug 12, 2023

Machine learning model could enable targeted gene therapies for genetic diseases

Posted by in categories: bioengineering, biotech/medical, genetics, mathematics, robotics/AI

Though almost every cell in your body contains a copy of each of your genes, only a small fraction of these genes will be expressed, or turned on. These activations are controlled by specialized snippets of DNA called enhancers, which act like skillful on-off switches. This selective activation allows cells to adopt specific functions in the body, determining whether they become—for example—heart cells, muscle cells, or brain cells.

However, these don’t always turn on the right at the right time, contributing to the development of genetic diseases like cancer and diabetes. A team of Johns Hopkins biomedical engineers has developed a that can predict which enhancers play a role in normal development and disease—an innovation that could someday power the development of enhancer-targeted therapies to treat diseases by turning genes on and off at will. The study results appeared in Nature Genetics.

“We’ve known that enhancers control transitions between for a long time, but what is exciting about this work is that mathematical modeling is showing us how they might be controlled,” said study leader Michael Beer, a professor of biomedical engineering and genetic medicine at Johns Hopkins University.

Aug 12, 2023

Synthetic biology and artificial intelligence are set to change all aspects of our lives

Posted by in categories: bioengineering, biotech/medical, chemistry, ethics, genetics, law, robotics/AI

Reichman University’s new Innovation Institute, which is set to formally open this spring under the auspices of the new Graziella Drahi Innovation Building, aims to encourage interdisciplinary, innovative and applied research as a cooperation between the different academic schools. The establishment of the Innovation Institute comes along with a new vision for the University, which puts the emphasis on the fields of synthetic biology, Artificial Intelligence (AI) and Advanced Reality (XR). Prof. Noam Lemelshtrich Latar, the Head of the Institute, identifies these as fields of the future, and the new Innovation Institute will focus on interdisciplinary applied research and the ramifications of these fields on the subjects that are researched and taught at the schools, for example, how law and ethics influence new medical practices and scientific research.

Synthetic biology is a new interdisciplinary field that integrates biology, chemistry, computer science, electrical and genetic engineering, enabling fast manipulation of biological systems to achieve a desired product.

Prof. Lemelshtrich Latar, with Dr. Jonathan Giron, who was the Institute’s Chief Operating Officer, has made a significant revolution at the University, when they raised a meaningful donation to establish the Scojen Institute for Synthetic Biology. The vision of the Scojen Institute is to conduct applied scientific research by employing top global scientists at Reichman University to become the leading synthetic biology research Institute in Israel. The donation will allow recruiting four world-leading scientists in various scopes of synthetic biology in life sciences. The first scientist and Head of the Scojen Institute has already been recruited – Prof. Yosi Shacham Diamand, a leading global scientist in bio-sensors and the integration of electronics and biology. The Scojen Institute labs will be located in the Graziella Drahi Innovation Building and will be one part of the future Dina Recanati School of Medicine, set to open in the academic year 2024–2025.

Aug 11, 2023

Multiple sclerosis: How a probiotic could help with MS treatment

Posted by in categories: bioengineering, biotech/medical, health, neuroscience

Researchers looking into the health benefits of utilizing gut bacteria say they have bioengineered a probiotic that may be useful as a treatment for multiple sclerosis.

Aug 11, 2023

New method a step toward future 3D printing of human tissues

Posted by in categories: 3D printing, bioengineering, biotech/medical

A team of bioengineers and biomedical scientists from the University of Sydney and the Children’s Medical Research Institute (CMRI) at Westmead have used 3D photolithographic printing to create a complex environment for assembling tissue that mimics the architecture of an organ.

The teams were led by Professor Hala Zreiqat and Dr. Peter Newman at the University of Sydney’s School of Biomedical Engineering and developmental biologist Professor Patrick Tam who leads the CMRI’s Embryology Research Unit. Their paper was published in Advanced Science.

Continue reading “New method a step toward future 3D printing of human tissues” »

Aug 11, 2023

MaxCyte signs strategic platform license with prime medicine to advance next-generation gene editing therapies for patients

Posted by in categories: bioengineering, biotech/medical, genetics

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced the signing of a strategic partnership with Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies.

Aug 10, 2023

New gene editing tool helps zero in on small cancer-linked mutations

Posted by in categories: bioengineering, biotech/medical, chemistry, genetics

A change in just one letter in the code that makes up a cancer-causing gene can significantly affect how aggressive a tumor is or how well a patient with cancer responds to a particular therapy. A new, very precise gene-editing tool created by Weill Cornell Medicine investigators will enable scientists to study the impact of these specific genetic changes in preclinical models rather than being limited to more broadly targeted tactics, such as deleting the entire gene.

The tool was described in a study published Aug. 10 in Nature Biotechnology. Dr. Lukas Dow, an associate professor of biochemistry in medicine at Weill Cornell Medicine, and his colleagues genetically engineered to carry an enzyme that allows the scientists to change a single base or “letter” in the mouse’s genetic code. The enzyme can be turned on or off by feeding the mice an antibiotic called doxycycline, reducing the prospect of unintended genetic changes occurring over time. The tool can also grow miniature versions of intestine, lung, and pancreas tissue called organoids from the mice, enabling even more molecular and biochemical studies of the impact of these precise genetic changes.

“We are excited about using this technology to try and understand the genetic changes that influence a patient’s response to therapies,” said Dr. Dow, who is also a member of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine.

Page 12 of 197First910111213141516Last